Global Autoinjectors Market (2nd Edition), 2018-2030

  • ID: 4580471
  • Report
  • Region: Global
  • 510 Pages
  • Roots Analysis
1 of 5
Over 85 Autoinjector Devices (33% Reusable / 67% Disposable), Including Variants of Individual Products, are Presently Being Manufactured By Close to 20 Companies.

FEATURED COMPANIES

  • AbbVie
  • Bayer
  • DALI Medical Devices
  • Janssen Biotech
  • Ompi - Stevanato Group
  • Shire
  • MORE

Over the years, the self-injection devices market has grown into a promising segment of the pharmaceutical industry. The domain is presently characterized by the presence of advanced technology platforms and innovative devices, offering a variety of user-friendly drug delivery solutions. One of the major driving forces behind the growth in this field is the rising incidence of chronic clinical conditions, such as rheumatoid arthritis, multiple sclerosis and diabetes. Although various pharmacological interventions are available for the treatment of these conditions, they require parenteral administration, frequent hospital visits, and are associated with multiple concerns, such as dosing and medication errors, risk of microbial contamination and needlestick injuries. However, therapies developed in combination with self-administration enabling devices have witnessed high adoption rates and have actually resulted in marked improvements in adherence to prescribed therapeutic regimens. In addition, such devices have been widely utilized in the treatment of emergency conditions such as anaphylaxis and other allergic disorders.

Since the introduction of the first autoinjector device in 1980s, their numerous benefits, such as ease-of-use, reduced chances of dosing errors, integrated safety mechanisms, and almost negligible risk of needlestick injuries, have been widely recognized among consumers and healthcare service providers. Autoinjectors are also considered to be potential life cycle management tool. Drugs nearing patent expiry can be developed for delivery using an autoinjector and retain market exclusivity as a combination product. Lyophilized Enbrel® is a well-known example; it was reformulated for delivery as a liquid formulation in the Sureclick™ autoinjector, extending its patent age by almost 11 years.

It is worth highlighting that such devices have captured the interest of several stakeholders in the industry. Various initiatives are underway to further improve safety, add better features (such as controlled-release capabilities) and make these devices more patient-friendly. In fact, between January 2013 and December 2017, close to 3,800 patents were filed in this domain, indicating the rapid pace at which research is being carried out. We believe that such efforts are likely to boost the overall growth of this market in the coming years.

The ‘Global Autoinjectors Market (2nd Edition), 2018-2030’ report provides a comprehensive analysis of the current state of the autoinjectors market and the likely future evolution of these devices over the next decade. The study presents an in-depth analysis of a diverse set of companies that are engaged in this domain across different regions of the globe.

Amongst other elements, the report includes:

  • A review of the overall landscape of the autoinjectors market, highlighting the contributions of industry players and the key device specifications, including the primary drug container used, its volume, usability of the device, route of administration, indication and targeted drugs.
  • An in-depth patent analysis to provide an overview on how the industry has evolved from the R&D perspective. For this analysis, we looked at the patents that have been published since 2013. The analysis also highlights key information associated with these patents, such as patent type, regional distribution, CPC classification, IP litigations, emerging areas and leading industry players.
  • A comprehensive product competitiveness analysis of disposable and reusable autoinjectors taking into consideration the supplier power (based on size of employee base) and product specifications, such as route of administration, primary drug container used, mechanism of operation, dosage type and user friendliness.
  • Comprehensive profiles of autoinjector manufacturers that have more than three devices in their respective product portfolios; each profile features an overview of the company, its financial information (if available), information on its product portfolio, autoinjector device specifications, collaborations, recent developments and a comprehensive future outlook. Additionally, the report includes brief profiles of emerging players that have been established in the past decade.
  • Detailed case studies on the most commonly targeted indications, covering history of development and detailed description of the approved autoinjector products, along with their respective mechanisms of action and historical sales records. In addition, we have listed all the drugs that are currently being delivered through autoinjectors.
  • A list of marketed and pipeline candidates that are likely to be developed in combination with autoinjectors in the near future; the candidate drugs / therapies were selected based on various parameters, such as their current route of administration, target therapeutic indication and dosage. For the purpose of this analysis, we collated a list of over 100 top-selling marketed drugs, which were initially screened on the basis of route of administration (subcutaneous / intramuscular). Additionally, we reviewed over 900 clinical trials and compiled a list of pipeline molecules that are being investigated for delivery via the aforementioned routes. The likelihood of delivery via autoinjector device in the future was estimated by assigning a specific score (weight) to each parameter.
  • A SWOT analysis capturing the key parameters and trends that are likely to influence the future of autoinjectors market.

One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for autoinjector devices. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market over the period 2018-2030. The report provides sales forecasts for the overall autoinjectors market with detailed market segmentation on the basis of indication (anaphylaxis / multiple sclerosis / rheumatoid arthritis / migraine / diabetes / other indications), route of administration (subcutaneous / intramuscular), usability (disposable / reusable) and the geographical distribution of the market (North America / Europe / Asia Pacific / rest of the World). In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base and optimistic scenarios, which represent three different tracks of the industry’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with David Daily (CEO and Co-founder, DALI Medical Devices), Tsachi Shaked (Senior Marketing and BD Director, Injectable Drug Delivery Devices, Elcam Medical) and Douglas Marenzi (Managing Director, PHC). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights

  • Over 85 autoinjector devices (33% reusable / 67% disposable), including variants of individual products, are presently being manufactured by close to 20 companies. 22% of these devices are designed to deliver a variable dose of drug.
  • 75 drug-autoinjector combination products are commercially available; amongst these, 30% received marketing approval between 2015 and 2017. Over 30 devices have been approved to cater to the rising demand for convenient delivery options for the treatment of chronic clinical conditions, such as multiple sclerosis and rheumatoid arthritis / psoriasis. These are followed by devices that are used to administer drugs for the treatment of anaphylaxis, organophosphate poisoning, migraine, growth hormone deficiency and diabetes. In addition, products are also approved for multiple other indications, such as cardiac arrhythmias, anxiety disorders, opioid overdose and systemic lupus erythematosus.
  • Notable examples of such combination products include (no selection criteria) Auvi-Q® (Kaléo Pharma), Avonex Pen® (Biogen Idec), BYDUREON BCise (AstraZeneca), EpiPen® (Mylan / Meridian Medical Technologies), Imitrex STATdose Pen® (GlaxoSmithKline) ORENCIA® ClickJect™ (Bristol-Myers Squibb), PRALUENT® (Sanofi), TRIPLEPEN HAD (ChemProtect SK), Trulicity® (Eli Lilly / Sumitomo Dainippon Pharma) and VIBEX® Sumatriptan (Antares Pharma / Teva Pharmaceutical).
  • A number of novel technology platforms are presently being utilized for the development of autoinjectors with advanced features, such as integrated sharps handling and controlled rate of injection. Examples of such technologies (no selection criteria) include Breeze™ technology (Nuance Designs), Depot Control technology (Union Medico), VapourSoft™ and ASI® technology (Bespak), and Rotaject™ Pressure Release technology, NIT™ technology and Pushclick™ technology (SHL Group).
  • As a result of the widening research interest, close to 3,800 patents have been filed recently. A detailed analysis of these patents indicates that automated self-injection devices, with advanced features, are gradually becoming mainstream. Some of these features include push-on-skin release, one-handed operation, twist and mix mechanism, automatic reconstitution / priming, anti-roll, compact and sleek design, LCD screens, and Bluetooth and other connectivity platforms.  Examples of autoinjectors that have been designed to be connected to smart devices include (in alphabetical order) GROWJECTOR®2 (JCR Pharmaceuticals), Flexi-eMU (Elcam Medical), RebiSmart™ (EMD Serono) and YpsoMate® Smart (Ypsomed).
  • A comprehensive analysis of several marketed / pipeline products suggests that over 100 drugs (not currently available in autoinjectors) are suited for delivery via autoinjectors. Most of these drugs target chronic conditions, require frequent dosing and are available for delivery via subcutaneous / intramuscular routes. We believe that these clinical candidates, if evaluated with autoinjectors, are likely to contribute substantially to the market's evolution in the mid-long term.
  • As more drug-device combination products get approved for a diverse range of indications, we expect the market to steadily evolve over the next decade. North America (primarily the US) and Europe currently capture the largest share (close to 75%) of the market. Launch in emerging regions, such as India and China, availability of such devices for other chronic (in addition to multiple sclerosis and rheumatoid arthritis) and emergency indications (in addition to anaphylaxis), introduction of life cycle management projects for drugs nearing patent expiry are some of the opportunity areas wherein the companies are likely to focus on.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie
  • Bayer
  • DALI Medical Devices
  • Janssen Biotech
  • Ompi - Stevanato Group
  • Shire
  • MORE

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Drug Delivery Systems
3.3. Conventional Parenteral Delivery
3.4. Needlestick Injuries
3.4.1. Incidence and Cost Burden
3.4.2. Prevention
3.4.3. Government Legislation for the Prevention of Needlestick Injuries
3.5. Self-Administration: An Emerging Trend
3.5.1 Factors Influencing Emergence of Self-Administration
3.5.1.1. Rising Burden of Chronic Diseases
3.5.1.2. Saving on Healthcare Costs
3.5.1.3. Need for Immediate Treatment in Emergency Situations
3.5.1.4. Expansion of Injectable Biologic Products
3.6. Safety Options in Self-Injectors
3.7 Types of Self-Injection Devices
3.7.1. Prefilled Syringes
3.7.2. Pen-Injectors
3.7.3. Needle-Free Injectors
3.7.4. Autoinjectors
3.7.5. Large Volume Wearable Injectors
3.8. Autoinjectors: An Important Class of Self-Injection Devices
3.8.1. Components of Autoinjectors
3.8.2. Classification of Autoinjectors
3.8.3. Manufacturing/Packaging
3.8.4. Benefits of Autoinjectors
3.8.5. Regulatory Considerations
3.8.6. Drug Device Combination Products
3.9. Concluding Remarks

4. PRIMARY DRUG CONTAINERS IN AUTOINJECTORS
4.1. Chapter Overview
4.2. Introduction to Primary Drug Containers
4.3 Types of Primary Drug Containers
4.3.1. Vials
4.3.2. Cartridges
4.3.2.1 Components
4.3.2.2. Types
4.3.2.3. Single Chamber Cartridges
4.3.2.4. Dual Chamber Cartridges
4.3.2.5. Applications
4.3.2.6. Drawbacks
4.3.2.7. Cartridges Available in the Market
4.3.3. Prefilled Syringes
4.3.3.1. Components
4.3.3.2. Classification
4.3.3.2.1. Based on Barrel Material
4.3.3.2.2. Based on Number of Chambers
4.3.3.2.3. Based on Type of Needle
4.3.3.3. Benefits
4.3.3.3.1. Over Traditional Injectable Devices
4.3.3.3.2. For Healthcare Professionals and End Users
4.3.3.3.3. For Manufacturers
4.3.3.4. Drawbacks
4.3.3.5. Prefilled Syringe Systems Available in the Market
4.3.3.5.1. Glass Prefilled Syringes
4.3.3.5.2. Plastic Prefilled Syringes

5. AUTOINJECTORS: CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Autoinjectors: Overall Market Overview
5.2.1. Distribution by Developers
5.2.2. Distribution by Type of Primary Drug Container
5.2.3. Distribution by Usability
5.2.4. Distribution by Dosage Type
5.2.5. Distribution by Route of Administration
5.2.6. Distribution by Volume of Container
5.3. Approved Combination Products: Overall Market Overview
5.3.1. Distribution by Developers
5.3.2. Distribution by Target Indication
5.3.3. Distribution by Type of Primary Drug Container
5.3.4.Distribution by Usability
5.3.5. Distribution by Route of Administration
5.3.6. Distribution by Target Drug
5.4. Pipeline Combination Products: Overall Market Overview
5.4.1.Grid Analysis: Distribution by Target Indication, Phase of Development and Route of Administration

6. PATENT ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Autoinjectors: Patent Analysis
6.3.1. Analysis by Publication Year
6.3.2. Analysis by Patent Offices
6.3.3. Analysis by CPC Classifications
6.3.4. Emerging Areas
6.3.5. Leading Players Based on Number of Patents
6.4. Autoinjectors: Patent Benchmarking Analysis
6.4.1. Analysis by Patent Characteristics
6.4.2. Analysis by Geography
6.5. Autoinjectors: Patent Valuation Analysis
6.6. Leading Patents Based on Number of Citations

7. CASE STUDIES
7.1. Chapter Overview
7.2. Marketed / Pipeline Drugs Being Evaluated with Autoinjectors
7.3 Case Study I: Anaphylaxis
7.3.1. Overview and Epidemiology
7.3.2. Mechanism of Action of Approved Drugs
7.3.3  History of Development of Approved Drugs
7.3.4. Autoinjectors Marketed for Anaphylaxis
7.3.4.1  Adrenaclick®
7.3.4.2. Allerject / Auvi-Q® (Formerly called e-cue™)
7.3.4.3.  Anapen®
7.3.4.4. Emerade®
7.3.4.5. EpiPen® / EpiPen® Jr
7.3.4.6. Jext®
7.3.5. Autoinjectors under Development for Anaphylaxis
7.3.5.1. EpiQ
7.3.5.2  Abiliject
7.3.5.3. MiniEpi
7.3.5.4. Zeneo® Adrenaline
7.3.6. Other Dosage Forms of Approved Drugs
7.3.7 Historical Sales of Approved Drugs / Autoinjectors
7.4. Case Study II: Multiple Sclerosis
7.4.1. Overview and Epidemiology
7.4.2. Mechanism of Action of Approved Drugs
7.4.3. History of Development of Approved Drugs
7.4.4. Autoinjectors Marketed for Multiple Sclerosis
7.4.4.1. Avonex Pen®
7.4.4.2. PLEGRIDY Pen
7.4.4.3. Rebif ® Rebidose ®
7.4.4.4. RebiSmart™
7.4.4.5. Rebiject II®
7.4.4.6. ReciGen® Physioject™
7.4.4.7. BETACONNECT™
7.4.4.8. BETAJECT® Comfort / Betacomfort®
7.4.4.9. Betaject® Lite
7.4.4.10. ExtaviJect® 30G / ExtaviPro® 30G
7.4.5. Other Dosage Forms of Approved Drugs
7.4.6. Historical Sales of Approved Drugs / Autoinjectors
7.5. Case Study III: Migraine
7.5.1. Overview and Epidemiology
7.5.2. Mechanism of Action of Approved Drugs
7.5.3. History of Development of Approved Drugs
7.5.4. Autoinjectors Marketed for Migraine
7.5.4.1. ALSUMA®
7.5.4.2. IMITREX STATdose Pen®
7.5.4.3. Zembrace SymTouch
7.5.5. Other Dosage Forms of Approved Drugs
7.5.6. Historical Sales of Approved Drugs / Autoinjectors
7.6. Case Study IV: Rheumatoid Arthritis
7.6.1. Overview and Epidemiology
7.6.2. History of Development of Approved Drugs
7.6.3. Autoinjectors Marketed for Rheumatoid Arthritis
7.6.3.1. Actemra®
7.6.3.2. CIMZIA® AutoClicks® Prefilled Pen
7.6.3.3. Enbrel SureClick®
7.6.3.4. HUMIRA® Pen
7.6.3.5. ORENCIA® ClickJect™
7.6.3.6. OTREXUP™
7.6.3.7. Rasuvo® Autoinjector
7.6.3.8. SIMPONI® SmartJect® Autoinjector
7.6.4. Historical Sales of Approved Drugs / Autoinjectors

8. LIKELY DRUG CANDIDATES FOR DELIVERY VIA AUTOINJECTORS
8.1. Chapter Overview
8.2. Marketed Molecules
8.2.1. Most Likely Candidates for Delivery Via Autoinjectors
8.2.2. Likely Candidates for Delivery Via Autoinjectors
8.2.3. Less Likely Candidates for Delivery Via Autoinjectors
8.2.4. Unlikely Candidates for Delivery Via Autoinjectors
8.3. Pipeline Molecules
8.3.1. Most Likely Candidates for Delivery Via Autoinjectors
8.3.2. Likely Candidates for Delivery Via Autoinjectors
8.3.3. Less Likely Candidates for Delivery Via Autoinjectors
8.3.4. Unlikely Candidates for Delivery Via Autoinjectors

9. KEY PLAYERS
9.1. Chapter Overview
9.2. Antares Pharma
9.2.1. Company Overview
9.2.2. Financial Information
9.2.3. Product Portfolio
9.2.3.1. Autoinjectors: Product Details
9.2.3.1.1. Vibex™
9.2.3.1.2. QuickShot™
9.2.3.1.3. BigShot™
9.2.4. Collaborations
9.2.5. Recent Developments and Future Outlook
9.3. Company Overview
9.3.2. Financial Information
9.3.3. Technology Overview
9.3.4. Product Portfolio
9.3.4.1. Autoinjectors: Product Details
9.3.4.1.1. Syrina™
9.3.4.2. OTS™ Autoinjector
9.3.5. Collaborations
9.3.6. Recent Developments and Future Outlook
9.4. DALI Medical Devices
9.4.1. Company Overview
9.4.2. Product Portfolio
9.4.2.1. Autoinjectors: Product Details
9.4.2.1.1. SAN-L
9.4.2.1.2. SAN-P
9.4.2.1.3. SAN-DV
9.4.2.1.4. SAN-DV Pro
9.4.3. Collaborations
9.4.4. Recent Developments and Future Outlook
9.5. Elcam Medical (E3D Elcam Drug Delivery Devices)
9.5.1. Company Overview
9.5.2. Product Portfolio
9.5.3. Autoinjectors: Product Details
9.5.3.1. Flexi-Q Disposable Autoinjectors
9.5.3.1.1. Flexi-Q PFS
9.5.3.1.2. Flexi-Q HV
9.5.3.1.3. Flexi -Q DV
9.5.3.2. Flexi-Q Reusable Autoinjectors
9.5.3.2.1. Flexi-Q mMU
9.5.3.2.2. Flexi-Q eMU-C / P
9.5.5. Collaborations
9.5.6. Recent Developments and Future Outlook
9.6. Jiangsu Delfu Medical Devices
9.6. Company Overview
9.6.2. Financial Information
9.6.3Product Portfolio
9.6.3.3. Autoinjectors: Product Details
9.6.3.3.1. YZ-II 3mLCartridge Digital Dose Setting GF Autoinjector
9.6.3.3.2. DZ-IA 3 mL Cartridge Needle Hidden Vaccination Autoinjector
9.6.3.3.3. DZ-IA Auto Injector Pen
9.6.3.3.4. Intravitreal Anti-VEGF Injections Electric Insulin Pens
9.6.3.3.5. YZ-III Standard 3 mL Cartridge Reusable Electronic Auto Injector Pen
9.6.3.3.6. YZ-III 0.001mL Dose Increments Fully Automated Reusable Injectors
9.6.3.3.7. YZ-III 0.001 mL Dose Accuracy Auto Injector Pen
9.6.3.3.8. YZ-II 3mL* 1u Auto Inject Pen
9.6.3.3.9. YZ-V 3 mL Cartridge Replaceable Variable-dose Classic Auto Injector Pen
9.6.3.3.10. YZ-III Automatic Reusable Insulin Injection Pen
9.6.4. Recent Developments and Future Outlook
9.7. Meridian Medical Technologies
9.7.1. Company Overview
9.7.2. Technology Overview
9.7.3. Product Portfolio
9.7.3.1. Autoinjectors: Product Details
9.7.3.1.1. Antidote Treatment Nerve Agent Autoinjector (ATNAA)
9.7.3.1.2. AtroPen® Autoinjector
9.7.3.1.3. Diazepam Autoinjector C-IV
9.7.3.1.4. DuoDote® Autoinjector
9.7.3.1.5. Morphine Autoinjector C-II
9.7.3.1.6. Pralidoxime Chloride Autoinjector
9.7.3.1.8. EpiPen® / EpiPen® Jr
9.7.3.1.9. ALSUMA® / Sumatriptan Autoinjector
9.7.3.1.10. Investigational Midazolam Autoinjector
9.7.4. Recent Developments and Future Outlook
9.8. Owen Mumford
9.8.1. Company Overview
9.8.2. Product Portfolio
9.8.2.1. Autoinjectors: Product Details
9.8.2.1.1. Autoject® Micro
9.8.2.1.2. Autoject® 2
9.8.2.1.3. Autoject® Mini
9.8.2.1.4. Autoject Uni
9.8.2.1.5. Autoject Multi
9.8.2.1.6. Autoject® Flex
9.8.3. Collaborations
9.8.4. Recent Developments and Future Outlook
9.9. SHL Group
9.9.1. Company Overview
9.9.2. Product Portfolio
9.9.2.1. Two-Step Disposable Autoinjectors: Product Details
9.9.2.1.1. Amber® (Pushclick™ Technology)
9.9.2.1.2. Molly®
9.9.2.1.3. Molly®RNS
9.9.2.1.4. Molly® 2.25
9.9.2.1.5. Molly® C
9.9.2.1.6. Rotaject®
9.9.2.1.7. Bertha®
9.9.2.1.8. DAI® 2
9.9.2.1.9. Maggie®
9.9.2.2. Three-Step Disposable Autoinjectors: Product Details
9.9.2.2.1. DAI®
9.9.2.2.2. DAI®-RNS
9.9.2.2.3. DAI®-R
9.9.2.2.4. SDI-MIX®+NIT™
9.9.2.2.5. VSDI-MIX™
9.9.2.2.6. PPI® Injector (Rotaject™ Pressure Release Technology)
9.9.3. Collaborations
9.9.4. Recent Developments and Future Outlook
9.10. Union Medico
9.10.1. Company Overview
9.10.2. Technology Overview
9.10.3. Product Portfolio
9.10.3.1. Autoinjectors: Product Details
9.10.3.1.1. 45˚ Autoinjector
9.10.3.1.2. 45˚/ S Autoinjector
9.10.3.1.3. 45˚/ M Autoinjector
9.10.3.1.4. 45˚/ R Autoinjector
9.10.3.1.5. Comparison of 45˚ Autoinjectors
9.10.3.1.6. 90˚Autoinjector
9.10.3.1.7. 90˚/ S Autoinjector
9.10.3.1.8. 90˚/ M Autoinjector
9.10.3.1.9. 90˚/ XL Autoinjector
9.10.3.1.10. SuperGrip™ Autoinjector
9.10.3.1.11. Exclusive™ Autoinjector
9.10.3.1.12. Comparison of 90˚ Autoinjectors
9.10.4. Recent Developments and Future Outlook
9.11. Ypsomed
9.11.1. Company Overview
9.11.2. Financial Information
9.11.3. Product Portfolio
9.11.3.1 Autoinjectors: Product Details
9.11.3.1.1. YpsoMate® and YpsoMate® 2.25
9.11.3.1.2. VarioJect™
9.11.3.1.3. YpsoMate® Smart
9.11.3.1.4. Comparison of Autoinjectors
9.11.4. Collaborations
9.11.5. Recent Developments and Future Outlook

10. EMERGING PLAYERS
10.1. Chapter Overview
10.2. AktiVax
10.3. Future Injection Technologies
10.4. Impax Laboratories (Amedra Pharmaceuticals)
10.5. Kaléo Pharma
10.6. MiniEpi
10.7. Nemera
10.8. Nuance Designs
10.9. Oval Medical Technologies
10.10. Windgap Medical
10.11. Xeris Pharmaceuticals
10.12. Zion Clinical Pharmacy

11. SWOT ANALYSIS
11.1. Chapter Overview
11.2. Strengths
11.3. Weaknesses
11.4. Opportunities
11.5. Threats

12. MARKET SIZING AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Global Autoinjectors Market
12.2.1. Global Autoinjectors Market, 2018-2030 (By Value)
12.2.1.1. Global Autoinjectors Market: Distribution by Usability, 2018-2030 (By Value)
12.2.1.2. Global Autoinjectors Market: Distribution by Route of Administration, 2018-2030 (By Value)
12.2.2. Autoinjectors Market in North America, 2018-2030 (By Value)
12.2.2.1. Autoinjectors Market in North America: Distribution by Usability, 2018-2030 (By Value)
12.2.2.2. Autoinjectors Market in North America: Distribution by Route of Administration, 2018-2030 (By Value)
12.2.3. Autoinjectors Market in Europe, 2018-2030 (By Value)
12.2.3.1. Autoinjectors Market in Europe: Distribution by Usability, 2018-2030 (By Value)
12.2.3.2. Autoinjectors Market in Europe: Distribution by Route of Administration, 2018-2030 (By Value)
12.2.4. Autoinjectors Market in Asia Pacific, 2018-2030 (By Value)
12.2.4.1. Autoinjectors Market in Asia Pacific: Distribution by Usability, 2018-2030 (By Value)
12.2.4.2. Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2018-2030 (By Value)
12.2.5.  Autoinjectors Market in Rest of the World, 2018-2030 (By Value)
12.2.5.1. Autoinjectors Market in Rest of the World: Distribution by Usability, 2018-2030 (By Value)
12.2.5.2. Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2018-2030 (By Value)
12.2.6. Global Autoinjectors Market, 2018-2030 (By Volume)
12.2.6.1. Global Autoinjectors Market: Distribution by Usability, 2018-2030 (By Volume)
12.2.6.2. Global Autoinjectors Market: Distribution by Route of Administration, 2018-2030 (By Volume)
12.2.7. Autoinjectors Market in North America, 2018-2030 (By Volume)
12.2.7.1. Autoinjectors Market in North America: Distribution by Usability, 2018-2030 (By Volume)
12.2.7.2. Autoinjectors Market in North America: Distribution by Route of Administration, 2018-2030 (By Volume)
12.2.8. Autoinjectors Market in Europe, 2018-2030 (By Volume)
12.2.8.1. Autoinjectors Market in Europe: Distribution by Usability, 2018-2030 (By Volume)
12.2.8.2. Autoinjectors Market in Europe: Distribution by Route of Administration, 2018-2030 (By Volume)
12.2.9. Autoinjectors Market in Asia Pacific, 2018-2030 (By Volume)
12.2.9.1. Autoinjectors Market in Asia Pacific: Distribution by Usability, 2018-2030 (By Volume)
12.2.9.2. Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2018-2030 (By Volume)
12.2.10. Autoinjectors Market in Rest of the World, 2018-2030 (By Volume)
12.2.10.1. Autoinjectors Market in Rest of the World: Distribution by Usability, 2018-2030 (By Volume)
12.2.10.2. Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2018-2030 (By Volume)
12.3. Autoinjectors Market for Anaphylaxis
12.3.1. Global Autoinjectors Market for Anaphylaxis, 2018-2030 (By Value)
12.3.2. Autoinjectors Market for Anaphylaxis in North America, 2018-2030 (By Value)
12.3.2.1. Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2018-2030 (By Value)
12.3.2.2. Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2018-2030 (By Value)
12.3.3. Autoinjectors Market for Anaphylaxis in Europe, 2018-2030 (By Value)
12.3.3.1. Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2018-2030 (By Value)
12.3.3.2. Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2018-2030 (By Value)
12.3.4. Autoinjectors Market for Anaphylaxis in Asia Pacific, 2018-2030 (By Value)
12.3.4.1. Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2018-2030 (By Value)
12.3.4.2. Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (By Value)
12.3.5. Autoinjectors Market for Anaphylaxis in Rest of the World, 2018-2030 (By Value)
12.3.5.1. Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2018-2030 (By Value)
12.3.5.2. Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2018-2030 (By Value)
12.3.6. Global Autoinjectors Market for Anaphylaxis, 2018-2030 (By Volume)
12.3.7. Autoinjectors Market for Anaphylaxis in North America, 2018-2030 (By Volume)
12.3.7.1. Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2018-2030 (By Volume)
12.3.7.2. Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2018-2030 (By Volume)
12.3.8. Autoinjectors Market for Anaphylaxis in Europe, 2018-2030 (By Volume)
12.3.8.1. Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2018-2030 (By Volume)
12.3.8.2. Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2018-2030 (By Volume)
12.3.9. Autoinjectors Market for Anaphylaxis in Asia Pacific, 2018-2030 (By Volume)
12.3.9.1. Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2018-2030 (By Volume)
12.3.9.2. Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (By Volume)
12.3.10. Autoinjectors Market for Anaphylaxis in Rest of the World, 2018-2030 (By Volume)
12.3.10.1. Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2018-2030 (By Volume)
12.3.10.2. Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2018-2030 (By Volume)
12.4. Autoinjectors Market for Multiple Sclerosis
12.4.1. Global Autoinjectors Market for Multiple Sclerosis, 2018-2030 (By Value)
12.4.2. Autoinjectors Market for Multiple Sclerosis in North America, 2018-2030 (By Value)
12.4.2.1. Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2018-2030 (By Value)
12.4.2.2. Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2018-2030 (By Value)
12.4.3. Autoinjectors Market for Multiple Sclerosis in Europe, 2018-2030 (By Value)
12.4.3.1. Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2018-2030 (By Value)
12.4.3.2. Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2018-2030 (By Value)
12.4.4. Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2018-2030 (By Value)
12.4.4.1. Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2018-2030 (By Value)
12.4.4.2. Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (By Value)
12.4.5. Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2018-2030 (By Value)
12.4.5.1. Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2018-2030 (By Value)
12.4.5.2. Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2018-2030 (By Value)
12.4.6. Global Autoinjectors Market for Multiple Sclerosis, 2018-2030 (By Volume)
12.4.7. Autoinjectors Market for Multiple Sclerosis in North America, 2018-2030 (By Volume)
12.4.7.1. Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2018-2030 (By Volume)
12.4.7.2. Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2018-2030 (By Volume)
12.4.8. Autoinjectors Market for Multiple Sclerosis in Europe, 2018-2030 (By Volume)
12.4.8.1. Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2018-2030 (By Volume)
12.4.8.2. Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2018-2030 (By Volume)
12.4.9. Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2018-2030 (By Volume)
12.4.9.1. Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2018-2030 (By Volume)
12.4.9.2. Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (By Volume)
12.4.10. Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2018-2030 (By Volume)
12.4.10.1. Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2018-2030 (By Volume)
12.4.10.2. Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2018-2030 (By Volume)
12.5. Autoinjectors Market for Rheumatoid Arthritis
12.5.1. Global Autoinjectors Market for Rheumatoid Arthritis, 2018-2030 (By Value)
12.5.2. Autoinjectors Market for Rheumatoid Arthritis in North America, 2018-2030 (By Value)
12.5.2.1. Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2018-2030 (By Value)
12.5.2.2. Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2018-2030 (By Value)
12.5.3. Autoinjectors Market for Rheumatoid Arthritis in Europe, 2018-2030 (By Value)
12.5.3.1. Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2018-2030 (By Value)
12.5.3.2. Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2018-2030 (By Value)
12.5.4. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2018-2030 (By Value)
12.5.4.1. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2018-2030 (By Value)
12.5.4.2. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (By Value)
12.5.5. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2018-2030 (By Value)
12.5.5.1. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2018-2030 (By Value)
12.5.5.2. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2018-2030 (By Value)
12.5.6. Global Autoinjectors Market for Rheumatoid Arthritis, 2018-2030 (By Volume)
12.5.7. Autoinjectors Market for Rheumatoid Arthritis in North America, 2018-2030 (By Volume)
12.5.7.1. Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2018-2030 (By Volume)
12.5.7.2. Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2018-2030 (By Volume)
12.5.8. Autoinjectors Market for Rheumatoid Arthritis in Europe, 2018-2030 (By Volume)
12.5.8.1. Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2018-2030 (By Volume)
12.5.8.2. Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2018-2030 (By Volume)
12.5.9. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2018-2030 (By Volume)
12.5.9.1. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2018-2030 (By Volume)
12.5.9.2. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (By Volume)
12.5.10. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2018-2030 (By Volume)
12.5.10.1. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2018-2030 (By Volume)
12.5.10.2. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2018-2030 (By Volume)
12.6. Autoinjectors Market for Migraine
12.6.1. Global Autoinjectors Market for Migraine, 2018-2030 (By Value)
12.6.2. Autoinjectors Market for Migraine in North America, 2018-2030 (By Value)
12.6.2.1. Autoinjectors Market for Migraine in North America: Distribution by Usability, 2018-2030 (By Value)
12.6.2.2. Autoinjectors Market for Migraine in North America: Distribution by Route of Administration, 2018-2030 (By Value)
12.6.3. Autoinjectors Market for Migraine in Europe, 2018-2030 (By Value)
12.6.3.1. Autoinjectors Market for Migraine in Europe: Distribution by Usability, 2018-2030 (By Value)
12.6.3.2. Autoinjectors Market for Migraine in Europe: Distribution by Route of Administration, 2018-2030 (By Value)
12.6.4. Autoinjectors Market for Migraine in Asia Pacific, 2018-2030 (By Value)
12.6.4.1. Autoinjectors Market for Migraine in Asia Pacific: Distribution by Usability, 2018-2030 (By Value)
12.6.4.2. Autoinjectors Market for Migraine in Asia Pacific: Distribution by Route of Administration, 2018-2030 (By Value)
12.6.5. Autoinjectors Market for Migraine in Rest of the World, 2018-2030 (By Value)
12.6.5.1. Autoinjectors Market for Migraine in Rest of the World: Distribution by Usability, 2018-2030 (By Value)
12.6.5.2. Autoinjectors Market for Migraine in Rest of the World: Distribution by Route of Administration, 2018-2030 (By Value)
12.6.6. Global Autoinjectors Market for Migraine, 2018-2030 (By Volume)
12.6.7. Autoinjectors Market for Migraine in North America, 2018-2030 (By Volume)
12.6.7.1. Autoinjectors Market for Migraine in North America: Distribution by Usability, 2018-2030 (By Volume)
12.6.7.2. Autoinjectors Market for Migraine in North America: Distribution by Route of Administration, 2018-2030 (By Volume)
12.6.8. Autoinjectors Market for Migraine in Europe, 2018-2030 (By Volume)
12.6.8.1. Autoinjectors Market for Migraine in Europe: Distribution by Usability, 2018-2030 (By Volume)
12.6.8.2. Autoinjectors Market for Migraine in Europe: Distribution by Route of Administration, 2018-2030 (By Volume)
12.6.9. Autoinjectors Market for Migraine in Asia Pacific, 2018-2030 (By Volume)
12.6.9.1. Autoinjectors Market for Migraine in Asia Pacific: Distribution by Usability, 2018-2030 (By Volume)
12.6.9.2. Autoinjectors Market for Migraine in Asia Pacific: Distribution by Route of Administration, 2018-2030 (By Volume)
12.6.10. Autoinjectors Market for Migraine in Rest of the World, 2018-2030 (By Volume)
12.6.10.1.  Autoinjectors Market for Migraine in Rest of the World: Distribution by Usability, 2018-2030 (By Volume)
12.6.10.2. Autoinjectors Market for Migraine in Rest of the World: Distribution by Route of Administration, 2018-2030 (By Volume)
12.7. Autoinjectors Market for Diabetes
12.7.1. Global Autoinjectors Market for Diabetes, 2018-2030 (By Value)
12.7.2. Autoinjectors Market for Diabetes in North America, 2018-2030 (By Value)
12.7.2.1. Autoinjectors Market for Diabetes in North America: Distribution by Usability, 2018-2030 (By Value)
12.7.2.2. Autoinjectors Market for Diabetes in North America: Distribution by Route of Administration, 2018-2030 (By Value)
12.7.3. Autoinjectors Market for Diabetes in Europe, 2018-2030 (By Value)
12.7.3.1. Autoinjectors Market for Diabetes in Europe: Distribution by Usability, 2018-2030 (By Value)
12.7.3.2. Autoinjectors Market for Diabetes in Europe: Distribution by Route of Administration, 2018-2030 (By Value)
12.7.4. Autoinjectors Market for Diabetes in Asia Pacific, 2018-2030 (By Value)
12.7.4.1. Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Usability, 2018-2030 (By Value)
12.7.4.2. Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Route of Administration, 2018-2030 (By Value)
12.7.5. Autoinjectors Market for Diabetes in Rest of the World, 2018-2030 (By Value)
12.7.5.1. Autoinjectors Market for Diabetes in Rest of the World: Distribution by Usability, 2018-2030 (By Value)
12.7.5.2. Autoinjectors Market for Diabetes in Rest of the World: Distribution by Route of Administration, 2018-2030 (By Value)
12.7.6. Global Autoinjectors Market for Diabetes, 2018-2030 (By Volume)
12.7.7. Autoinjectors Market for Diabetes in North America, 2018-2030 (By Volume)
12.7.7.1. Autoinjectors Market for Diabetes in North America: Distribution by Usability, 2018-2030 (By Volume)
12.7.7.2. Autoinjectors Market for Diabetes in North America: Distribution by Route of Administration, 2018-2030 (By Volume)
12.7.8. Autoinjectors Market for Diabetes in Europe, 2018-2030 (By Volume)
12.7.8.1. Autoinjectors Market for Diabetes in Europe: Distribution by Usability, 2018-2030 (By Volume)
12.7.8.2. Autoinjectors Market for Diabetes in Europe: Distribution by Route of Administration, 2018-2030 (By Volume)
12.7.9. Autoinjectors Market for Diabetes in Asia Pacific, 2018-2030 (By Volume)
12.7.9.1. Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Usability, 2018-2030 (By Volume)
12.7.9.2. Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Route of Administration, 2018-2030 (By Volume)
12.7.10. Autoinjectors Market for Diabetes in Rest of the World, 2018-2030 (By Volume)
12.7.10.1. Autoinjectors Market for Diabetes in Rest of the World: Distribution by Usability, 2018-2030 (By Volume)
12.7.10.2. Autoinjectors Market for Diabetes in Rest of the World: Distribution by Route of Administration, 2018-2030 (By Volume)
12.8. Autoinjectors Market for Other Indications
12.8.1. Global Autoinjectors Market for Other Indications, 2018-2030 (By Value)
12.8.2. Autoinjectors Market for Other Indications in North America, 2018-2030 (By Value)
12.8.2.1. Autoinjectors Market for Other Indications in North America: Distribution by Usability, 2018-2030 (By Value)
12.8.2.2. Autoinjectors Market for Other Indications in North America: Distribution by Route of Administration, 2018-2030 (By Value)
12.8.3. Autoinjectors Market for Other Indications in Europe, 2018-2030 (By Value)
12.8.3.1. Autoinjectors Market for Other Indications in Europe: Distribution by Usability, 2018-2030 (By Value)
12.8.3.2. Autoinjectors Market for Other Indications in Europe: Distribution by Route of Administration, 2018-2030 (By Value)
12.8.4. Autoinjectors Market for Other Indications in Asia Pacific, 2018-2030 (By Value)
12.8.4.1. Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Usability, 2018-2030 (By Value)
12.8.4.2. Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Route of Administration, 2018-2030 (By Value)
12.8.5. Autoinjectors Market for Other Indications in Rest of the World, 2018-2030 (By Value)
12.8.5.1. Autoinjectors Market for Other Indications in Rest of the World: Distribution by Usability, 2018-2030 (By Value)
12.8.5.2. Autoinjectors Market for Other Indications in Rest of the World: Distribution by Route of Administration, 2018-2030 (By Value)
12.8.6. Global Autoinjectors Market for Other Indications, 2018-2030 (By Volume)
12.8.7. Autoinjectors Market for Other Indications in North America, 2018-2030 (By Volume)
12.8.7.1. Autoinjectors Market for Other Indications in North America: Distribution by Usability, 2018-2030 (By Volume)
12.8.7.2. Autoinjectors Market for Other Indications in North America: Distribution by Route of Administration, 2018-2030 (By Volume)
12.8.8. Autoinjectors Market for Other Indications in Europe, 2018-2030 (By Volume)
12.8.8.1. Autoinjectors Market for Other Indications in Europe: Distribution by Usability, 2018-2030 (By Volume)
12.8.8.2. Autoinjectors Market for Other Indications in Europe: Distribution by Route of Administration, 2018-2030 (By Volume)
12.8.9. Autoinjectors Market for Other Indications in Asia Pacific, 2018-2030 (By Volume)
12.8.9.1. Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Usability, 2018-2030 (By Volume)
12.8.9.2. Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Route of Administration, 2018-2030 (By Volume)
12.8.10. Autoinjectors Market for Other Indications in Rest of the World, 2018-2030 (By Volume)
12.8.10.1. Autoinjectors Market for Other Indications in Rest of the World: Distribution by Usability, 2018-2030 (By Volume)
12.8.10.2. Autoinjectors Market for Other Indications in Rest of the World: Distribution by Route of Administration, 2018-2030 (By Volume)

13. CONCLUSION
13.1. Rising Incidence of Chronic Illnesses has Augmented the Demand for Devices that Enable Self-Medication
13.2. Given their Numerous Benefits, Autoinjectors have Emerged as Potent Drug Delivery Tools
13.3. Several Combination Products have Already been Approved and Many are Under Development
13.4. Majority of the Available Products are Disposable; However, Reusable Devices are Gradually Gaining Popularity
13.5. Although the Market is Led by the Well-Established Players, Start-Ups Continue to Spearhead the Innovation in this Field
13.6. Led by Several Growth Opportunities, the Market is Expected to Evolve at a Steady Pace over the Coming Decade

14. INTERVIEW TRANSCRIPTS
14.1. Chapter Overview
14.2. PHC
14.2.1. Company Snapshot
14.2.2. Interview Transcript: Douglas Marenzi, Managing Director, PHC 
14.3. Elcam Medical
14.3.1. Company Snapshot
14.3.2. Interview Transcript: Tsachi Shaked, Senior Marketing and BD Director, Injectable Drug Delivery Devices, Elcam Medical
14.4. DALI Medical Devices
14.4.1. Company Snapshot
14.4.2. Interview Transcript: David Daily, CEO and Co-Founder, DALI Medical Devices

15. APPENDIX 1: TABULATED DATA

16.APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures
Figure 3.1  Popular Drug Delivery Systems
Figure 3.2  Types of Self-Injection Devices
Figure 3.3  Cartridge Based Autoinjectors v/s Prefilled Syringe Based Autoinjectors
Figure 3.4  Components of Autoinjectors
Figure 3.5  Classification of Autoinjectors
Figure 4.1   Dual Chamber Cartridges
Figure 4.2  Glass Prefilled Syringes: Advantages and Disadvantages
Figure 4.3  Plastic Prefilled Syringes: Advantages and Disadvantages
Figure 5.1  Autoinjectors: Distribution by Developers
Figure 5.2  Autoinjectors: Distribution by Type of Primary Drug Container
Figure 5.3  Autoinjectors: Distribution by Usability
Figure 5.4  Autoinjectors: Distribution by Dosage Type
Figure 5.5  Autoinjectors: Distribution by Route of Administration
Figure 5.6  Autoinjectors: Distribution by Volume of Container
Figure 5.7  Approved Combination Products: Distribution by Developers
Figure 5.8  Approved Combination Products: Distribution by Target Indication
Figure 5.9  Approved Combination Products: Distribution by Type of Primary Drug Container
Figure 5.10  Approved Combination Products: Distribution by Usability
Figure 5.11 Approved Combination Products: Distribution by Route of Administration
Figure 5.12  Approved Combination Products: Distribution by Target Drug
Figure 5.13  Pipeline Combination Products: Grid Analysis, Distribution by Target Indication, Phase of Development and Route of Administration 
Figure 6.1  Patent Portfolio: Distribution by Type of Patent
Figure 6.2  Patent Portfolio: Cumulative Distribution by Publication Year
Figure 6.3  Patent Portfolio: Distribution by Regions
Figure 6.4  Patent Portfolio: Distribution by CPC Classification Symbol
Figure 6.5  Patent Portfolio: Emerging Areas
Figure 6.6  Patent Portfolio: Distribution by Leading Assignees
Figure 6.7  Patent Portfolio: Geographical Distribution of Leading Players
Figure 6.8  Patent Portfolio: Benchmarking by Patent Characteristics
Figure 6.9  Patent Portfolio: Benchmarking by International Patents
Figure 6.10  Patent Portfolio: Distribution by Age of Patents (January 2013-October 2017)
Figure 6.11  Patent Portfolio: Valuation Analysis
Figure 7.1  Anaphylaxis: History of Development of Approved Drugs
Figure 7.2  Anaphylaxis: Historical Sales of Approved Drugs / Autoinjectors (USD Billion), 2012-2017
Figure 7.3  Multiple Sclerosis: History of Development of Approved Drugs
Figure 7.4  Multiple Sclerosis: Historical Sales of Approved Drugs / Autoinjectors (USD Billion), 2012-2017
Figure 7.5  Migraine: History of Development of Approved Drugs
Figure 7.6  Migraine: Historical Sales of Approved Drugs / Autoinjectors (USD Million), 2015-2017
Figure 7.7  Rheumatoid Arthritis: History of Development of Approved Drugs
Figure 7.8  Rheumatoid Arthritis: Historical Sales of Approved Drugs / Autoinjectors (USD Billion), 2015-2017
Figure 8.1  Likely Candidates for Delivery Via Autoinjectors: Relative Scoring of Marketed Drugs
Figure 8.2  Likely Candidates for Delivery Via Autoinjectors: Relative Scoring of Pipeline Drugs
Figure 9.1  Antares Pharma: Annual Revenues, 2012-2017 (USD Million)
Figure 9.2  Antares Pharma: Product Portfolio
Figure 9.3  Bespak: Annual Revenues, FY 2012/13-FY 2016/17 (GBP Million)
Figure 9.4  Bespak Injectables: Syrina™ Autoinjectors
Figure 9.5  DALI Medical Devices: Autoinjectors
Figure 9.6  DALI Medical Devices: Steps of Operation of SAN-L
Figure 9.7  DALI Medical Devices: Steps of Operation of SAN-P
Figure 9.8  DALI Medical Devices: Steps of Operation of SAN-DV
Figure 9.9  DALI Medical Devices: Steps of Operation of SAN-DV Pro
Figure 9.10  Elcam Medical: Product Portfolio
Figure 9.11  Elcam Medical: Flexi-Q Autoinjectors
Figure 9.12 Elcam Medical: Components of Flexi-Q PFS
Figure 9.13  Elcam Medical: Steps of Operation of Flexi-Q PFS
Figure 9.14  Elcam Medical: Components of Flexi-Q DV
Figure 9.15  Elcam Medical: Steps of Operation Flexi-Q DV
Figure 9.16  Elcam Medical: Components of Flexi-Q mMU
Figure 9.17  Elcam Medical: Components of Flexi-Q eMU
Figure 9.18  Elcam Medical: Steps of Operation of Flexi-Q mMU / Flexi-Q eMU
Figure 9.19  Jiangsu Delfu Medical Devices: Components of Autoinjectors
Figure 9.20  Jiangsu Delfu Medical Devices: Applications of Autoinjectors
Figure 9.21  Meridian Medical Technologies: Autoinjectors Portfolio
Figure 9.22  Meridian Medical Technologies: Steps of Operation of ATNAA
Figure 9.23  Meridian Medical Technologies: Step of Operation of Diazepam Autoinjector C-IV
Figure 9.24  Meridian Medical Technologies: Steps of Operation of DuoDote® Autoinjector
Figure 9.25  Meridian Medical Technologies: Steps of Operation of Morphine Autoinjector
Figure 9.26  Meridian Medical Technologies: Steps of Operation of Pralidoxime Chloride Autoinjector
Figure 9.27  Meridian Medical Technologies: Steps of Operation of EpiPen®:
Figure 9.28  Meridian Medical Technologies: Steps of Operation of ALSUMA® Autoinjector
Figure 9.29  Owen Mumford: Cartridge-Based Injection Pens
Figure 9.30 Owen Mumford: Autoinjectors Portfolio
Figure 9.31 Owen Mumford: Steps of Operation of Autoject® Micro
Figure 9.32 Owen Mumford: Steps of Operation of Autoject®2 Autoinjector
Figure 9.33 Owen Mumford: Steps of Operation of Autoject® Mini
Figure 9.34  Owen Mumford: Steps of Operation of Autoject® Uni
Figure 9.35  Owen Mumford: Steps of Operation of Autoject® Multi
Figure 9.36  Owen Mumford: Steps of Operation of Autoject® Flex
Figure 9.37  SHL Group: Product Portfolio
Figure 9.38  SHL Group: Prefilled Syringe Based Autoinjectors
Figure 9.39  SHL Group: Cartridge Based Autoinjectors
Figure 9.40 SHL Group: Two-Step Autoinjectors
Figure 9.41  SHL Group: Steps of Operation of Two-Step Autoinjectors
Figure 9.42  SHL Group: Three-Step Autoinjectors
Figure 9.43  SHL Group: Steps of Operation of DAI®
Figure 9.44  SHL Group: Steps of Operation of DAI®-R
Figure 9.45 SHL Group: Steps of Operation of SDI-MIX®+NIT™
Figure 9.46  Union Medico: Portfolio of 45˚ Autoinjectors
Figure 9.47  Union Medico: Parts of 45˚/R Autoinjector
Figure 9.48 Union Medico: Types of 45˚/R Autoinjector
Figure 9.49 Union Medico: Types of 90˚ Autoinjectors
Figure 9.50 Union Medico: Components of SuperGrip™
Figure 9.51 Union Medico: Components of Exclusive™
Figure 9.52  Ypsomed: Annual Revenues, FY 2012/13-FY 2017/18 (CHF Million)
Figure 9.53  Ypsomed: Sales by Business Divisions, FY 2016/17 (CHF Million, %)
Figure 9.54  Ypsomed: Product Portfolio
Figure 9.55  Ypsomed: Steps of Operation of YpsoMate®
Figure 9.56  Ypsomed: Steps of Operation of VarioJect™
Figure 9.57  Ypsomed: Steps of Operation of YpsoMate® Smart
Figure 11.1  Autoinjectors SWOT Analysis: Overview
Figure 11.2  Comparison of SWOT Factors: Harvey Ball Analysis
Figure 12.1  Global Autoinjectors Market, 2018-2030 (USD Million)
Figure 12.2  Global Autoinjectors Market: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.3  Global Autoinjectors Market: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.4  Autoinjectors Market in North America, 2018-2030 (USD Million)
Figure 12.5  Autoinjectors Market in North America: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.6  Autoinjectors Market in North America: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.7  Autoinjectors Market in Europe, 2018-2030 (USD Million)
Figure 12.8  Autoinjectors Market in Europe: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.9  Autoinjectors Market in Europe: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.10  Autoinjectors Market in Asia Pacific, 2018-2030 (USD Million)
Figure 12.11  Autoinjectors Market in Asia Pacific: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.12  Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.13  Autoinjectors Market in Rest of the World, 2018-2030 (USD Million)
Figure 12.14  Autoinjectors Market in Rest of the World: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.15  Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.16  Global Autoinjectors Market, 2018-2030 (Units, Million)
Figure 12.17  Global Autoinjectors Market: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.18  Global Autoinjectors Market: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.19  Autoinjectors Market in North America, 2018-2030 (Units, Million)
Figure 12.20  Autoinjectors Market in North America: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.21  Autoinjectors Market in North America: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.22  Autoinjectors Market in Europe, 2018-2030 (Units, Million)
Figure 12.23  Autoinjectors Market in Europe: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.24  Autoinjectors Market in Europe: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.25  Autoinjectors Market in Asia Pacific, 2018-2030 (Units, Million)
Figure 12.26  Autoinjectors Market in Asia Pacific: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.27  Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.28  Autoinjectors Market in Rest of the World, 2018-2030 (Units, Million)
Figure 12.29  Autoinjectors Market in Rest of the World: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.30  Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.31  Global Autoinjectors Market for Anaphylaxis, 2018-2030 (USD Million)
Figure 12.32  Autoinjectors Market for Anaphylaxis in North America, 2018-2030 (USD Million)
Figure 12.33  Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.34  Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.35  Autoinjectors Market for Anaphylaxis in Europe, 2018-2030 (USD Million)
Figure 12.36  Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.37  Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.38  Autoinjectors Market for Anaphylaxis in Asia Pacific, 2018-2030 (USD Million)
Figure 12.39  Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.40  Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.41  Autoinjectors Market for Anaphylaxis in Rest of the World, 2018-2030 (USD Million)
Figure 12.42  Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.43  Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.44  Global Autoinjectors Market for Anaphylaxis, 2018-2030 (Units, Million)
Figure 12.45  Autoinjectors Market for Anaphylaxis in North America, 2018-2030 (Units, Million)
Figure 12.46  Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.47  Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.48  Autoinjectors Market for Anaphylaxis in Europe, 2018-2030 (Units, Million)
Figure 12.49  Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.50  Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.51  Autoinjectors Market for Anaphylaxis in Asia Pacific, 2018-2030 (Units, Million)
Figure 12.52  Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.53  Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.54  Autoinjectors Market for Anaphylaxis in Rest of the World, 2018-2030 (Units, Million)
Figure 12.55  Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.56  Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.57  Global Autoinjectors Market for Multiple Sclerosis, 2018-2030 (USD Million)
Figure 12.58  Autoinjectors Market for Multiple Sclerosis in North America, 2018-2030 (USD Million)
Figure 12.59  Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.60  Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.61  Autoinjectors Market for Multiple Sclerosis in Europe, 2018-2030 (USD Million)
Figure 12.62  Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.63  Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.64  Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2018-2030 (USD Million)
Figure 12.65  Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.66  Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.67  Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2018-2030 (USD Million)
Figure 12.68  Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.69  Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.70  Global Autoinjectors Market for Multiple Sclerosis, 2018-2030 (Units, Million)
Figure 12.71  Autoinjectors Market for Multiple Sclerosis in North America, 2018-2030 (Units, Million)
Figure 12.72  Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.73  Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.74  Autoinjectors Market for Multiple Sclerosis in Europe, 2018-2030 (Units, Million)
Figure 12.75  Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.76  Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.77  Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2018-2030 (Units, Million)
Figure 12.78  Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.79  Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.80  Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2018-2030 (Units, Million)
Figure 12.81  Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.82  Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.83 Global Autoinjectors Market for Rheumatoid Arthritis, 2018-2030 (USD Million)
Figure 12.84  Autoinjectors Market for Rheumatoid Arthritis in North America, 2018-2030 (USD Million)
Figure 12.85  Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.86  Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.87  Autoinjectors Market for Rheumatoid Arthritis in Europe, 2018-2030 (USD Million)
Figure 12.88  Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.89  Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.90  Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2018-2030 (USD Million)
Figure 12.91  Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.92  Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.93  Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2018-2030 (USD Million)
Figure 12.94  Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.95  Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.96  Global Autoinjectors Market for Rheumatoid Arthritis, 2018-2030 (Units, Million)
Figure 12.97  Autoinjectors Market for Rheumatoid Arthritis in North America, 2018-2030 (Units, Million)
Figure 12.98  Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.99  Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.100  Autoinjectors Market for Rheumatoid Arthritis in Europe, 2018-2030 (Units, Million)
Figure 12.101  Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.102  Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.103  Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2018-2030 (Units, Million)
Figure 12.104  Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.105  Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.106  Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2018-2030 (Units, Million)
Figure 12.107  Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.108  Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.109  Global Autoinjectors Market for Migraine, 2018-2030 (USD Million)
Figure 12.110  Autoinjectors Market for Migraine in North America, 2018-2030 (USD Million)
Figure 12.111  Autoinjectors Market for Migraine in North America: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.112  Autoinjectors Market for Migraine in North America: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.113  Autoinjectors Market for Migraine in Europe, 2018-2030 (USD Million)
Figure 12.114  Autoinjectors Market for Migraine in Europe: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.115  Autoinjectors Market for Migraine in Europe: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.116  Autoinjectors Market for Migraine in Asia Pacific, 2018-2030 (USD Million)
Figure 12.117  Autoinjectors Market for Migraine in Asia Pacific: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.118  Autoinjectors Market for Migraine in Asia Pacific: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.119  Autoinjectors Market for Migraine in Rest of the World, 2018-2030 (USD Million)
Figure 12.120  Autoinjectors Market for Migraine in Rest of the World: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.121  Autoinjectors Market for Migraine in Rest of the World: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.122  Global Autoinjectors Market for Migraine, 2018-2030 (Units, Million)
Figure 12.123  Autoinjectors Market for Migraine in North America, 2018-2030 (Units, Million)
Figure 12.124  Autoinjectors Market for Migraine in North America: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.125  Autoinjectors Market for Migraine in North America: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.126  Autoinjectors Market for Migraine in Europe, 2018-2030 (Units, Million)
Figure 12.127  Autoinjectors Market for Migraine in Europe: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.128  Autoinjectors Market for Migraine in Europe: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.129  Autoinjectors Market for Migraine in Asia Pacific, 2018-2030 (Units, Million)
Figure 12.130  Autoinjectors Market for Migraine in Asia Pacific: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.131  Autoinjectors Market for Migraine in Asia Pacific: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.132  Autoinjectors Market for Migraine in Rest of the World, 2018-2030 (Units, Million)
Figure 12.133  Autoinjectors Market for Migraine in Rest of the World: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.134  Autoinjectors Market for Migraine in Rest of the World: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.135  Global Autoinjectors Market for Diabetes, 2018-2030 (USD Million)
Figure 12.136  Autoinjectors Market for Diabetes in North America, 2018-2030 (USD Million)
Figure 12.137  Autoinjectors Market for Diabetes in North America: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.138  Autoinjectors Market for Diabetes in North America: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.139  Autoinjectors Market for Diabetes in Europe, 2018-2030 (USD Million)
Figure 12.140  Autoinjectors Market for Diabetes in Europe: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.141  Autoinjectors Market for Diabetes in Europe: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.142  Autoinjectors Market for Diabetes in Asia Pacific, 2018-2030 (USD Million)
Figure 12.143  Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.144  Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.145  Autoinjectors Market for Diabetes in Rest of the World, 2018-2030 (USD Million)
Figure 12.146  Autoinjectors Market for Diabetes in Rest of the World: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.147  Autoinjectors Market for Diabetes in Rest of the World: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.148  Global Autoinjectors Market for Diabetes, 2018-2030 (Units, Million)
Figure 12.149  Autoinjectors Market for Diabetes in North America, 2018-2030 (Units, Million)
Figure 12.150  Autoinjectors Market for Diabetes in North America: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.151  Autoinjectors Market for Diabetes in North America: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.152 Autoinjectors Market for Diabetes in Europe, 2018-2030 (Units, Million)
Figure 12.153  Autoinjectors Market for Diabetes in Europe: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.154  Autoinjectors Market for Diabetes in Europe: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.155  Autoinjectors Market for Diabetes in Asia Pacific, 2018-2030 (Units, Million)
Figure 12.156  Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.157  Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.158  Autoinjectors Market for Diabetes in Rest of the World, 2018-2030 (Units, Million)
Figure 12.159  Autoinjectors Market for Diabetes in Rest of the World: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.160  Autoinjectors Market for Diabetes in Rest of the World: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.161  Global Autoinjectors Market for Other Indications, 2018-2030 (USD Million)
Figure 12.162  Autoinjectors Market for Other Indications in North America, 2018-2030 (USD Million)
Figure 12.163  Autoinjectors Market for Other Indications in North America: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.164  Autoinjectors Market for Other Indications in North America: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.165  Autoinjectors Market for Other Indications in Europe, 2018-2030 (USD Million)
Figure 12.166  Autoinjectors Market for Other Indications in Europe: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.167  Autoinjectors Market for Other Indications in Europe: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.168  Autoinjectors Market for Other Indications in Asia Pacific, 2018-2030 (USD Million)
Figure 12.169  Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.170  Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.171  Autoinjectors Market for Other Indications in Rest of the World, 2018-2030 (USD Million)
Figure 12.172  Autoinjectors Market for Other Indications in Rest of the World: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.173  Autoinjectors Market for Other Indications in Rest of the World: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.174  Global Autoinjectors Market for Other Indications, 2018-2030 (Units, Million)
Figure 12.175  Autoinjectors Market for Other Indications in North America, 2018-2030 (Units, Million)
Figure 12.176  Autoinjectors Market for Other Indications in North America: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.177  Autoinjectors Market for Other Indications in North America: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.178  Autoinjectors Market for Other Indications in Europe, 2018-2030 (Units, Million)
Figure 12.179  Autoinjectors Market for Other Indications in Europe: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.180  Autoinjectors Market for Other Indications in Europe: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.181  Autoinjectors Market for Other Indications in Asia Pacific, 2018-2030 (Units, Million)
Figure 12.182  Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.183  Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.184  Autoinjectors Market for Other Indications in Rest of the World, 2018-2030 (Units, Million)
Figure 12.185  Autoinjectors Market for Other Indications in Rest of the World: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.186  Autoinjectors Market for Other Indications in Rest of the World: Distribution by Route of Administration, 2018-2030 (Units, Million)

List of Tables:
Table 3.1  Comparison of Self-Injection Devices
Table 3.2  Benefits of Autoinjectors
Table 4.1  Cartridges Available in the Market, 2018
Table 4.2  Classification of Prefilled Syringes
Table 4.3  Glass Prefilled Syringes Available in the Market, 2018
Table 4.4 Plastic Prefilled Syringes Available in the Market, 2018
Table 5.1  List of Autoinjector Devices
Table 5.2  Autoinjectors: Distribution by Dosage Type
Table 5.3 List of Approved Combination Products
Table 5.4 List of Pipeline Combination Products
Table 6.1  Patent Portfolio: CPC Symbol Definitions
Table 6.2  Patent Portfolio: Most Popular CPC Symbols
Table 6.3  Patent Portfolio: List of Top CPC Classifications
Table 6.4  Patent Portfolio: Leading Citations
Table 7.1  Marketed / Pipeline Drugs Being Evaluated with Autoinjectors
Table 7.2  Anaphylaxis: Commercially Available Autoinjectors
Table 7.3  Anaphylaxis: Other Dosage Forms of Approved Drugs
Table 7.4  Multiple Sclerosis: Commercially Available Autoinjectors 
Table 7.5  Multiple Sclerosis: Other Dosage Forms of Approved Drugs
Table 7.6  Migraine: Commercially Available Autoinjectors
Table 7.7  Migraine: Other Dosage Forms of Approved Drugs
Table 7.8  Rheumatoid Arthritis: Commercially Available Autoinjectors
Table 8.1  Marketed Molecules: Most Likely Candidates for Delivery Via Autoinjectors
Table 8.2  Marketed Molecules: Likely Candidates for Delivery Via Autoinjectors
Table 8.3  Marketed Molecules: Less Likely Candidates for Delivery Via Autoinjectors
Table 8.4  Marketed Molecules: Unlikely Candidates for Delivery Via Autoinjectors
Table 8.5 Pipeline Molecules: Most Likely Candidates for Delivery Via Autoinjectors
Table 8.6 Pipeline Molecules: Likely Candidates for Delivery Via Autoinjectors
Table 8.7  Pipeline Molecules: Less Likely Candidates for Delivery Via Autoinjectors
Table 8.8  Pipeline Molecules: Unlikely Candidates for Delivery Via Autoinjectors
Table 9.1  Antares Pharma: Recent Developments and Future Outlook
Table 9.2  Bespak: Recent Developments and Future Outlook
Table 9.3  DALI Medical Devices: Recent Developments and Future Outlook
Table 9.4  Elcam Medical: Recent Developments and Future Outlook
Table 9.5  Jiangsu Delfu Medical Devices: Autoinjectors Portfolio
Table 9.6  Jiangsu Delfu Medical Devices: Specifications of Autoinjectors
Table 9.7  Meridian Medical Technologies: Constituents of Diluents in ATNAA
Table 9.8  Meridian Medical Technologies: Comparison of AtroPen® Autoinjectors (Based on Dose Strengths)
Table 9.9  Meridian Medical Technologies: Constituents of Diluent in Diazepam Autoinjector C-IV
Table 9.10  Meridian Medical Technologies: Constituents of Diluents in DuoDote® Autoinjector
Table 9.11  Meridian Medical Technologies: Constituents of Diluent in Morphine Autoinjector C-II
Table 9.12  Meridian Medical Technologies: Constituents of Diluent in Pralidoxime Chloride Autoinjector
Table 9.13  Meridian Medical Technologies: Comparison of Autoinjectors
Table 9.14  Owen Mumford: Comparison of AutoJect®2 Variants
Table 9.15  Owen Mumford: Comparison of Autoject® 2 Variants Based on Size of the Syringe
Table 9.16  Owen Mumford: Comparison of Autoject® Mini Variants Based on Usability
Table 9.17  Owen Mumford: Features of Autoject® Flex Variants
Table 9.18  Owen Mumford: Comparison of Autoinjectors
Table 9.19  Owen Mumford: Recent Developments and Future Outlook
Table 9.20  SHL Group: Comparison of Two-Step Disposable Autoinjectors
Table 9.21  SHL Group: Comparison of Three-Step Disposable Autoinjectors
Table 9.22 SHL Group: Recent Developments and Future Outlook
Table 9.23  Union Medico: Comparison of 45˚ Autoinjectors
Table 9.24  Union Medico: Comparison of 90˚ Autoinjectors
Table 9.25 Ypsomed: Comparison of Autoinjectors
Table 9.26  Ypsomed: Recent Developments and Future Outlook
Table 15.1  Autoinjectors: Distribution by Developers
Table 15.2  Autoinjectors: Distribution by Type of Primary Drug Container
Table 15.3  Autoinjectors: Distribution by Usability
Table 15.4  Autoinjectors: Distribution by Dosage Type
Table 15.5  Autoinjectors: Distribution by Route of Administration
Table 15.6  Autoinjectors: Distribution by Volume of Container
Table 15.7  Approved Combination Products: Distribution by Developers
Table 15.8  Approved Combination Products: Distribution by Target Indication
Table 15.9  Approved Combination Products: Distribution by Type of Primary Drug Container
Table 15.10  Approved Combination Products: Distribution by Usability
Table 15.11 Approved Combination Products: Distribution by Route of Administration
Table 15.12  Approved Combination Products: Distribution by Target Drug
Table 15.13  Patent Portfolio: Distribution by Type of Patent
Table 15.14 Patent Portfolio: Cumulative Distribution by Publication Year
Table 15.15 Patent Portfolio: Distribution by Regions
Table 15.16  Patent Portfolio: Distribution by Leading Assignees
Table 15.17 Anaphylaxis: Historical Sales of Approved Drugs / Autoinjectors (USD Billion), 2015-20115
Table 15.18 Multiple Sclerosis: Historical Sales of Approved Drugs / Autoinjectors (USD Billion), 2015-20115
Table 15.19  Migraine: Historical Sales of Approved Drugs / Autoinjectors (USD Million), 2015-20115
Table 15.20  Rheumatoid Arthritis: Historical Sales of Approved Drugs / Autoinjectors (USD Billion), 2015-20115
Table 15.21 Antares Pharma: Annual Revenues, 2015-20115 (USD Million)
Table 15.22 Bespak: Annual Revenues, FY 2015/13-FY 20115/115 (GBP Million)
Table 15.23 Ypsomed: Annual Revenues, FY 2015/13-FY 20115/18 (CHF Million)
Table 15.24 Ypsomed: Sales by Business Divisions, FY 20115/115 (CHF Million, %)
Table 15.25 Global Autoinjectors Market, 2018-2030 (USD Million)
Table 15.26 Global Autoinjectors Market: Distribution by Usability, 2018-2030 (USD Million)
Table 15.27 Global Autoinjectors Market: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.28 Autoinjectors Market in North America, 2018-2030 (USD Million)
Table 15.29  Autoinjectors Market in North America: Distribution by Usability, 2018-2030 (USD Million)
Table 15.30  Autoinjectors Market in North America: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.31  Autoinjectors Market in Europe, 2018-2030 (USD Million)
Table 15.32 Autoinjectors Market in Europe: Distribution by Usability, 2018-2030 (USD Million)
Table 15.33 Autoinjectors Market in Europe: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.3 Autoinjectors Market in Asia Pacific, 2018-2030 (USD Million)
Table 15.35 Autoinjectors Market in Asia Pacific: Distribution by Usability, 2018-2030 (USD Million)
Table 15.36 Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.37 Autoinjectors Market in Rest of the World, 2018-2030 (USD Million)
Table 15.38 Autoinjectors Market in Rest of the World: Distribution by Usability, 2018-2030 (USD Million)
Table 15.3 Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.40 Global Autoinjectors Market, 2018-2030 (Units, Million)
Table 15.41 Global Autoinjectors Market: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.42 Global Autoinjectors Market: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.43 Autoinjectors Market in North America, 2018-2030 (Units, Million)
Table 15.44 Autoinjectors Market in North America: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.45 Autoinjectors Market in North America: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.46 Autoinjectors Market in Europe, 2018-2030 (Units, Million)
Table 15.47 Autoinjectors Market in Europe: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.48 Autoinjectors Market in Europe: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.49  Autoinjectors Market in Asia Pacific, 2018-2030 (Units, Million)
Table 15.5 Autoinjectors Market in Asia Pacific: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.51 Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.52 Autoinjectors Market in Rest of the World, 2018-2030 (Units, Million)
Table 15.53 Autoinjectors Market in Rest of the World: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.54 Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.55 Global Autoinjectors Market for Anaphylaxis, 2018-2030 (USD Million)
Table 15.56  Autoinjectors Market for Anaphylaxis in North America, 2018-2030 (USD Million)
Table 15.57 Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2018-2030 (USD Million)
Table 15.58 Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.5 Autoinjectors Market for Anaphylaxis in Europe, 2018-2030 (USD Million)
Table 15.6 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2018-2030 (USD Million)
Table 15.61 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.62 Autoinjectors Market for Anaphylaxis in Asia Pacific, 2018-2030 (USD Million)
Table 15.63 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2018-2030 (USD Million)
Table 15.64  Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.6 Autoinjectors Market for Anaphylaxis in Rest of the World, 2018-2030 (USD Million)
Table 15.66 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2018-2030 (USD Million)
Table 15.67 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.68 Global Autoinjectors Market for Anaphylaxis, 2018-2030 (Units, Million)
Table 15.69 Autoinjectors Market for Anaphylaxis in North America, 2018-2030 (Units, Million)
Table 15.70 Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.71 Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.72  Autoinjectors Market for Anaphylaxis in Europe, 2018-2030 (Units, Million)
Table 15.7 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.74 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.75 Autoinjectors Market for Anaphylaxis in Asia Pacific, 2018-2030 (Units, Million)
Table 15.76 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.77 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.78 Autoinjectors Market for Anaphylaxis in Rest of the World, 2018-2030 (Units, Million)
Table 15.79 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.80  Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.81 Global Autoinjectors Market for Multiple Sclerosis, 2018-2030 (USD Million)
Table 15.82 Autoinjectors Market for Multiple Sclerosis in North America, 2018-2030 (USD Million)
Table 15.83 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2018-2030 (USD Million)
Table 15.84 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.85 Autoinjectors Market for Multiple Sclerosis in Europe, 2018-2030 (USD Million)
Table 15.86 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2018-2030 (USD Million)
Table 15.87 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.88  Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2018-2030 (USD Million)
Table 15.89 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2018-2030 (USD Million)
Table 15.90  Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.91 Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2018-2030 (USD Million)
Table 15.92  Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2018-2030 (USD Million)
Table 15.93   Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.94  Global Autoinjectors Market for Multiple Sclerosis, 2018-2030 (Units, Million)
Table 15.95  Autoinjectors Market for Multiple Sclerosis in North America, 2018-2030 (Units, Million)
Table 15.96  Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.97  Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.98 Autoinjectors Market for Multiple Sclerosis in Europe, 2018-2030 (Units, Million)
Table 15.99  Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.100  Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.101 Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2018-2030 (Units, Million)
Table 15.102  Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.103  Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.104  Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2018-2030 (Units, Million)
Table 15.105 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.106 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.107 Global Autoinjectors Market for Rheumatoid Arthritis, 2018-2030 (USD Million)
Table 15.108 Autoinjectors Market for Rheumatoid Arthritis in North America, 2018-2030 (USD Million)
Table 15.109 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2018-2030 (USD Million)
Table 15.110 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.111 Autoinjectors Market for Rheumatoid Arthritis in Europe, 2018-2030 (USD Million)
Table 15.112 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2018-2030 (USD Million)
Table 15.113 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.114 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2018-2030 (USD Million)
Table 15.115  Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2018-2030 (USD Million)
Table 15.116 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.11 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2018-2030 (USD Million)
Table 15.118 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2018-2030 (USD Million)
Table 15.119  Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.120  Global Autoinjectors Market for Rheumatoid Arthritis, 2018-2030 (Units, Million)
Table 15.12 Autoinjectors Market for Rheumatoid Arthritis in North America, 2018-2030 (Units, Million)
Table 15.122  Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.123  Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.124  Autoinjectors Market for Rheumatoid Arthritis in Europe, 2018-2030 (Units, Million)
Table 15.125  Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.126  Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.127  Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2018-2030 (Units, Million)
Table 15.128  Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.129  Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.130  Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2018-2030 (Units, Million)
Table 15.131  Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.132  Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.133 Global Autoinjectors Market for Migraine, 2018-2030 (USD Million)
Table 15.134 Autoinjectors Market for Migraine in North America, 2018-2030 (USD Million)
Table 15.135 Autoinjectors Market for Migraine in North America: Distribution by Usability, 2018-2030 (USD Million)
Table 15.136  Autoinjectors Market for Migraine in North America: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.137  Autoinjectors Market for Migraine in Europe, 2018-2030 (USD Million)
Table 15.138  Autoinjectors Market for Migraine in Europe: Distribution by Usability, 2018-2030 (USD Million)
Table 15.13  Autoinjectors Market for Migraine in Europe: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.140  Autoinjectors Market for Migraine in Asia Pacific, 2018-2030 (USD Million)
Table 15.141 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Usability, 2018-2030 (USD Million)
Table 15.142  Autoinjectors Market for Migraine in Asia Pacific: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.143  Autoinjectors Market for Migraine in Rest of the World, 2018-2030 (USD Million)
Table 15.144 Autoinjectors Market for Migraine in Rest of the World: Distribution by Usability, 2018-2030 (USD Million)
Table 15.14 Autoinjectors Market for Migraine in Rest of the World: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.146 Global Autoinjectors Market for Migraine, 2018-2030 (Units, Million)
Table 15.147 Autoinjectors Market for Migraine in North America, 2018-2030 (Units, Million)
Table 15.148 Autoinjectors Market for Migraine in North America: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.149  Autoinjectors Market for Migraine in North America: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.15 Autoinjectors Market for Migraine in Europe, 2018-2030 (Units, Million)
Table 15.151 Autoinjectors Market for Migraine in Europe: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.152 Autoinjectors Market for Migraine in Europe: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.153 Autoinjectors Market for Migraine in Asia Pacific, 2018-2030 (Units, Million)
Table 15.15 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.155 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.156 Autoinjectors Market for Migraine in Rest of the World, 2018-2030 (Units, Million)
Table 15.157 Autoinjectors Market for Migraine in Rest of the World: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.158 Autoinjectors Market for Migraine in Rest of the World: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.159 Global Autoinjectors Market for Diabetes, 2018-2030 (USD Million)
Table 15.160 Autoinjectors Market for Diabetes in North America, 2018-2030 (USD Million)
Table 15.161 Autoinjectors Market for Diabetes in North America: Distribution by Usability, 2018-2030 (USD Million)
Table 15.162 Autoinjectors Market for Diabetes in North America: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.16 Autoinjectors Market for Diabetes in Europe, 2018-2030 (USD Million)
Table 15.164 Autoinjectors Market for Diabetes in Europe: Distribution by Usability, 2018-2030 (USD Million)
Table 15.165 Autoinjectors Market for Diabetes in Europe: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.166 Autoinjectors Market for Diabetes in Asia Pacific, 2018-2030 (USD Million)
Table 15.167 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Usability, 2018-2030 (USD Million)
Table 15.168 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.169 Autoinjectors Market for Diabetes in Rest of the World, 2018-2030 (USD Million)
Table 15.170 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Usability, 2018-2030 (USD Million)
Table 15.171 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.172 Global Autoinjectors Market for Diabetes, 2018-2030 (Units, Million)
Table 15.173 Autoinjectors Market for Diabetes in North America, 2018-2030 (Units, Million)
Table 15.174 Autoinjectors Market for Diabetes in North America: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.175 Autoinjectors Market for Diabetes in North America: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.176 Autoinjectors Market for Diabetes in Europe, 2018-2030 (Units, Million)
Table 15.177 Autoinjectors Market for Diabetes in Europe: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.178 Autoinjectors Market for Diabetes in Europe: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.179 Autoinjectors Market for Diabetes in Asia Pacific, 2018-2030 (Units, Million)
Table 15.180 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.18 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.182 Autoinjectors Market for Diabetes in Rest of the World, 2018-2030 (Units, Million)
Table 15.183 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.184 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.18 Global Autoinjectors Market for Other Indications, 2018-2030 (USD Million)
Table 15.186 Autoinjectors Market for Other Indications in North America, 2018-2030 (USD Million)
Table 15.18 Autoinjectors Market for Other Indications in North America: Distribution by Usability, 2018-2030 (USD Million)
Table 15.18 Autoinjectors Market for Other Indications in North America: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.189 Autoinjectors Market for Other Indications in Europe, 2018-2030 (USD Million)
Table 15.190 Autoinjectors Market for Other Indications in Europe: Distribution by Usability, 2018-2030 (USD Million)
Table 15.191 Autoinjectors Market for Other Indications in Europe: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.192 Autoinjectors Market for Other Indications in Asia Pacific, 2018-2030 (USD Million)
Table 15.193 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Usability, 2018-2030 (USD Million)
Table 15.194 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.195 Autoinjectors Market for Other Indications in Rest of the World, 2018-2030 (USD Million)
Table 15.196 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Usability, 2018-2030 (USD Million)
Table 15.197 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.198 Global Autoinjectors Market for Other Indications, 2018-2030 (Units, Million)
Table 15.199 Autoinjectors Market for Other Indications in North America, 2018-2030 (Units, Million)
Table 15.200 Autoinjectors Market for Other Indications in North America: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.20 Autoinjectors Market for Other Indications in North America: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.20 Autoinjectors Market for Other Indications in Europe, 2018-2030 (Units, Million)
Table 15.20 Autoinjectors Market for Other Indications in Europe: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.20 Autoinjectors Market for Other Indications in Europe: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.205 Autoinjectors Market for Other Indications in Asia Pacific, 2018-2030 (Units, Million)
Table 15.206 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by  Usability, 2018-2030 (Units, Million)
Table 15.207 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.20 Autoinjectors Market for Other Indications in Rest of the World, 2018-2030 (Units, Million)
Table 15.209 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.210 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Route of Administration, 2018-2030 (Units, Million)

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AbbVie
  • Bayer
  • DALI Medical Devices
  • Janssen Biotech
  • Ompi - Stevanato Group
  • Shire
  • MORE

Research Methodology

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts’ views

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the autoinjectors market in the short-mid term and long term.

Chapter 3 provides a general overview of the various devices that enable self-injection of parenteral drugs, specifically focusing on autoinjectors. It features a discussion on the historical evolution of autoinjectors, along with details related to their individual components, device categories and associated manufacturing / packaging processes. In addition, it elaborates on the benefits of autoinjectors that have led to their growing adoption over the last several years. The chapter also highlights the existing concerns related to needlestick injuries and the various preventive laws that have been passed worldwide, for addressing the pressing need for introducing safety features in such devices.

Chapter 4 is an introduction to the various types of primary drug containers that are utilized in autoinjectors. It features an overview of current trends related to the use of prefilled syringes and cartridges. In addition, it lists the diverse types of primary drug containers that are available in the market, along with details on key manufacturers that are involved in the production of such containers.

Chapter 5 provides information on more than 85 autoinjectors that have already been developed or are under development. It features a comprehensive analysis of these devices based on different parameters, such as primary drug container used, volume, device usability, route of administration and other technical parameters. The chapter also includes a list of combination products that have been approved or are under development for various indications. For both disposable and reusable autoinjectors, we have presented detailed 2 X 2 matrices to compare product competitiveness, based on the supplier power (based on size of employee base) and product specifications, such as route of administration, primary drug container used, mechanism of operation, dosage type and user friendliness.

Chapter 6 provides an in-depth patent analysis, presenting an overview of how the industry is evolving from the R&D perspective. For this analysis, we looked at the patents that have been published by various players since 2013. The analysis highlights the key information associated with these patents, including patent type, regional distribution, CPC classification, IP litigations, emerging areas and the leading industry players.

Chapter 7 presents a list of therapeutic drugs that are currently available for delivery via autoinjectors. It also provides detailed case studies on the most commonly targeted indications covering history of development and detailed description of the approved autoinjector products, along with mechanism of action and historical sales of the drugs.

Chapter 8 presents a list of marketed and pipeline molecules that are likely to be considered for delivery via autoinjectors in the future. It is worth highlighting that this list was compiled based on various parameters, such as route of administration, target therapeutic indication and the current dosage regimen of the aforementioned product candidates. For the purpose of this analysis, we collated a list of over 100 top-selling marketed drugs, which were initially screened on the basis of route of administration (subcutaneous / intramuscular). Additionally, we reviewed over 900 clinical trials and compiled a list of pipeline molecules that are being investigated for delivery via the aforementioned routes. The likelihood of delivery via autoinjector device in the future was estimated by assigning a specific score (weight) to each parameter.

Chapter 9 provides detailed profiles of key autoinjector manufacturers. Each profile includes an overview of the company, its financial information (if available), overview of the autoinjector technology used, information on its product portfolio, specifications of autoinjectors devices, collaborations, recent developments and a comprehensive future outlook.

Chapter 10 provides brief profiles of certain emerging players in the autoinjectors industry. Each profile features an overview of the company, technology overview, information on product portfolio, details on the respective autoinjector devices and recent developments.

Chapter 11 presents a detailed analysis capturing the key parameters and trends that are likely to influence the future of autoinjectors market, under a comprehensive SWOT framework.

Chapter 12 presents a comprehensive market forecast analysis, highlighting the future potential of autoinjectors, till the year 2030. We have segregated the opportunity on the basis of indication (anaphylaxis / multiple sclerosis / rheumatoid arthritis / migraine / diabetes / other indications), route of administration (subcutaneous / intramuscular), usability (disposable / reusable) and the geographical distribution of the market (North America, Europe, Asia Pacific and rest of the World). Future sales and growth opportunity were estimated based on the likely adoption rates and the anticipated price of products. We have adopted a top down approach, backed by robust data and credible inputs from primary research, to estimates the likely size of the market, both in terms of value (USD billion) and volume (number of devices).

Chapter 13 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 14 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with (in alphabetical order of company name) David Daily (CEO and Co-founder, DALI Medical Devices, Tsachi Shaked (Senior Marketing and BD Director, Injectable Drug Delivery Devices, Elcam Medical) and Douglas Marenzi (Managing Director, PHC).

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 16 is an appendix, which provides a list of companies and organizations mentioned in this report.

Note: Product cover images may vary from those shown
5 of 5
  • AbbVie
  • Ablynx
  • Acceleron Pharma
  • Allergan
  • Acuitas Therapeutics
  • Aesica Pharmaceuticals
  • Laboratoire AGUETTANT
  • AktiVax
  • Alexion Pharmaceuticals
  • ALK-Abelló A/S
  • Allergy Therapeutics
  • Alnylam Pharmaceuticals
  • Alphamab Jilin
  • Alvogen
  • AMAG Pharmaceuticals
  • Amedra Pharmaceuticals
  • Amgen
  • Amneal Pharmaceuticals
  • Amylin Pharmaceuticals
  • Androsystems
  • AnGes
  • Antares Pharma
  • Antaros Medical
  • Aptar Pharma
  • Arrowhead Pharmaceuticals
  • Arte
  • Arteaus Therapeutics
  • Asahi Kasei Pharma
  • Ascendis Pharma
  • Astellas Pharma
  • AstraZeneca
  • Axon Neuroscience
  • Bay City Capital
  • Bayer
  • BD Medical
  • Beijing Dongfang Biotech
  • Bespak
  • Betta Pharmaceuticals
  • Biocad
  • Biocon
  • Biogen
  • BioGenCell
  • BioGene Pharmaceutical
  • BioLineRx
  • BioMarin Pharmaceutical
  • Bioprojet Pharma
  • Boehringer Ingelheim
  • Boston Pharmaceuticals
  • Bristol-Myers Squibb
  • Caladrius Biosciences
  • Cambridge Consultants
  • Celgene
  • Celltrion Healthcare
  • ChemProtect SK
  • Chugai Pharmaceutical
  • CinnaGen
  • Connected Health Services
  • Consort Medical
  • Corvidia Therapeutics
  • Creare
  • Crossject
  • CSL Behring
  • CuraVac
  • CytoDyn
  • Daikyo Seiko
  • DALI Medical Devices
  • Deerfield Management
  • DiaMedica Therapeutics
  • Disetronic Holding
  • Dr. Reddy's Laboratory
  • Eiger BioPharmaceuticals
  • Eisai
  • Elcam Medical
  • Elli Lilly
  • EMD Serono
  • Emergent BioSolutions
  • Ferring Pharmaceuticals
  • Future Injection Technologies
  • Galderma R&D
  • Genentech
  • Gerresheimer
  • Gilead Sciences
  • GlaxoSmithKline
  • Globe Medical Tech
  • HAL Allergy Group
  • Hanmi Pharmaceuticals
  • Haselmeier
  • Hoffmann-La Roche
  • Hospira
  • Idera Pharmaceuticals
  • Immune Response BioPharma
  • Immunex
  • Impax Laboratories
  • Injectech
  • Inmunotek
  • Innovent Biologics
  • Ionis Pharmaceuticals
  • Ipsen
  • Janssen Biotech
  • JCR Pharmaceuticals
  • Jerini
  • Jiangsu Delfu Medical Device
  • Kaléo
  • Kang Stem Biotech
  • KeyBioscience
  • King Pharmaceuticals
  • Kisling
  • Kyowa Hakko Kirin
  • LEO Pharma
  • Lineage Therapeutics
  • LyoGo
  • M3 Biotechnology
  • Meda Pharmaceuticals
  • Medac Pharma
  • Medeca Pharma
  • Medicom Innovation Partner
  • Medimop Medical Projects
  • MedPro Group
  • Merck
  • Meridian Medical Technologies
  • Mérieux Développement
  • MGlas
  • MiniEpi
  • Momenta Pharmaceuticals
  • Mylan
  • Nemera
  • NGM Biopharmaceuticals
  • Nipro PharmaPackaging
  • Nordic Bioscience
  • Novartis
  • Novo Nordisk
  • Nuance Designs
  • Ompi - Stevanato Group
  • OneWorld DMG
  • OPKO Biologics
  • Otsuka Pharmaceutical
  • Oval Medical Technologies
  • Owen Mumford
  • PA Consulting Group
  • Palatin Technologies
  • Palmetto Partners
  • Pfizer
  • PHC
  • Plas-Tech Engineering
  • Pluristem Therapeutics
  • PRA Health Sciences
  • ProJect Pharmaceutics
  • Promius Pharma
  • QuiO
  • RaviMed
  • Redmile Group
  • Regeneron Pharmaceuticals
  • REMD Biotherapeutics
  • Revolutions Medical
  • Rhythm Pharmaceuticals
  • Roselabs Bioscience
  • Samsung Bioepis
  • Sandoz
  • Sanofi
  • Santarus
  • Schott
  • Schreiner MediPharm
  • Serina Therapeutics
  • Shandong Weigao
  • Shire
  • SHL Group
  • SiliCycle
  • SiO2 Medical Products
  • SK Chemicals
  • SKINSORB Cosmetics
  • SMC
  • Stealth BioTherapeutics
  • Sumitomo Dainippon Pharma
  • Sun Pharmaceutical
  • Survival Technologies
  • Synthon Hisapania
  • TaiMed Biologics
  • Taisei Kako
  • Takeda Pharmaceutical
  • Terumo
  • Teva Pharmaceutical Industries
  • The Medical House
  • The Medicines Company
  • Thinfilm Electronics
  • Tolmar
  • Tonghua Dongbao Pharmaceutical
  • TSH Biopharm
  • UCB Biopharma
  • Ultragenyx Pharmaceutical
  • Uman Pharma
  • Unilife
  • Union Medico
  • US Medical Instruments
  • US WorldMeds
  • Valeant Pharmaceuticals International
  • Vetter Pharma
  • ViiV Healthcare
  • Vitaeris
  • West Pharmaceutical Services
  • Wild Basin Investments
  • Windgap Medical
  • Xeris Pharmaceuticals
  • Ypsomed
  • Zafgen
  • Zion Clinic Pharmacy
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll